December 20, 2018

Precision BioSciences Appoints Rare Disease Executive Shalini Sharp to Its Board of Directors

DURHAM, N.C.–(BUSINESS WIRE)–Dec 20, 2018–Precision BioSciences, a genome editing company dedicated to improving life, announced today that industry veteran Shalini Sharp has joined the company’s Board of Directors. An established business leader in the life sciences industry, Sharp is the Chief Financial Officer (CFO) and Executive Vice President of Ultragenyx Pharmaceutical. Sharp brings a wealth of experience in financial management and corporate strategy in rare disease, gene therapy and oncology.

“We are thrilled to welcome Shalini Sharp to the Precision BioSciences Board of Directors,” said Precision CEO Matt Kane. “Shalini’s broad understanding of the financial markets within rare disease and oncology will be invaluable as Precision progresses into clinical trials of its genome-edited product portfolio.”

“I am excited to work with Precision as the company develops new therapies based on its next generation gene editing technology, ARCUS, which has the potential to help patients achieve better outcomes,” said Sharp. “I have also been impressed by the scaled manufacturing process Precision has developed, which is a critical and sometimes overlooked factor.”

Read more

Back to News